nebnext umi rna adapters Search Results


nebnext ultra ii rna library prep kit  (New England Biolabs)
96
New England Biolabs nebnext ultra ii rna library prep kit
Nebnext Ultra Ii Rna Library Prep Kit, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nebnext ultra ii rna library prep kit/product/New England Biolabs
Average 96 stars, based on 1 article reviews
nebnext ultra ii rna library prep kit - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
sars cov 2 panel 2  (Integrated DNA Technologies)
92
Integrated DNA Technologies sars cov 2 panel 2
Study design and sampling time points. Participants included naïve and convalescent individuals given either two or three doses of Pfizer vaccine; a convalescent individual given the J&J vaccine; and unvaccinated convalescent individuals. Viral RNA, antibodies against S or N proteins, and inhibition capacities against the viral receptor-binding domain (RBD) of <t>SARS-CoV-2</t> were evaluated at T1 (2 weeks post the first dose) and T2 (2 weeks post the second dose) in individual participants. At T3 (24 weeks post the first dose or ~5 months postvaccination) and T4 (36 weeks post the first dose or ~8 months postvaccination), viral RNA, antibodies against S or N proteins of SARS-CoV-2, and neutralizing antibodies were evaluated by live-virus-based microneutralization assay. Since the Delta variant emerged (around T3), we evaluated neutralization capacities against the basal B.1 virus (original SARS-CoV-2) and the Delta variant. The Delta variant became the dominant variant ( ⩾ 99%) as most of our participants were reaching T4, thus, we mainly focused on the Delta variant at this time point. Participants gradually received BNT162b2 booster shots after T3 until the endpoint of our study.
Sars Cov 2 Panel 2, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sars cov 2 panel 2/product/Integrated DNA Technologies
Average 92 stars, based on 1 article reviews
sars cov 2 panel 2 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier
adapters  (New England Biolabs)
96
New England Biolabs adapters
Study design and sampling time points. Participants included naïve and convalescent individuals given either two or three doses of Pfizer vaccine; a convalescent individual given the J&J vaccine; and unvaccinated convalescent individuals. Viral RNA, antibodies against S or N proteins, and inhibition capacities against the viral receptor-binding domain (RBD) of <t>SARS-CoV-2</t> were evaluated at T1 (2 weeks post the first dose) and T2 (2 weeks post the second dose) in individual participants. At T3 (24 weeks post the first dose or ~5 months postvaccination) and T4 (36 weeks post the first dose or ~8 months postvaccination), viral RNA, antibodies against S or N proteins of SARS-CoV-2, and neutralizing antibodies were evaluated by live-virus-based microneutralization assay. Since the Delta variant emerged (around T3), we evaluated neutralization capacities against the basal B.1 virus (original SARS-CoV-2) and the Delta variant. The Delta variant became the dominant variant ( ⩾ 99%) as most of our participants were reaching T4, thus, we mainly focused on the Delta variant at this time point. Participants gradually received BNT162b2 booster shots after T3 until the endpoint of our study.
Adapters, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adapters/product/New England Biolabs
Average 96 stars, based on 1 article reviews
adapters - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
nebnext primer mix  (New England Biolabs)
93
New England Biolabs nebnext primer mix
Study design and sampling time points. Participants included naïve and convalescent individuals given either two or three doses of Pfizer vaccine; a convalescent individual given the J&J vaccine; and unvaccinated convalescent individuals. Viral RNA, antibodies against S or N proteins, and inhibition capacities against the viral receptor-binding domain (RBD) of <t>SARS-CoV-2</t> were evaluated at T1 (2 weeks post the first dose) and T2 (2 weeks post the second dose) in individual participants. At T3 (24 weeks post the first dose or ~5 months postvaccination) and T4 (36 weeks post the first dose or ~8 months postvaccination), viral RNA, antibodies against S or N proteins of SARS-CoV-2, and neutralizing antibodies were evaluated by live-virus-based microneutralization assay. Since the Delta variant emerged (around T3), we evaluated neutralization capacities against the basal B.1 virus (original SARS-CoV-2) and the Delta variant. The Delta variant became the dominant variant ( ⩾ 99%) as most of our participants were reaching T4, thus, we mainly focused on the Delta variant at this time point. Participants gradually received BNT162b2 booster shots after T3 until the endpoint of our study.
Nebnext Primer Mix, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nebnext primer mix/product/New England Biolabs
Average 93 stars, based on 1 article reviews
nebnext primer mix - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
nebnext umi rna adaptors  (New England Biolabs)
96
New England Biolabs nebnext umi rna adaptors
Study design and sampling time points. Participants included naïve and convalescent individuals given either two or three doses of Pfizer vaccine; a convalescent individual given the J&J vaccine; and unvaccinated convalescent individuals. Viral RNA, antibodies against S or N proteins, and inhibition capacities against the viral receptor-binding domain (RBD) of <t>SARS-CoV-2</t> were evaluated at T1 (2 weeks post the first dose) and T2 (2 weeks post the second dose) in individual participants. At T3 (24 weeks post the first dose or ~5 months postvaccination) and T4 (36 weeks post the first dose or ~8 months postvaccination), viral RNA, antibodies against S or N proteins of SARS-CoV-2, and neutralizing antibodies were evaluated by live-virus-based microneutralization assay. Since the Delta variant emerged (around T3), we evaluated neutralization capacities against the basal B.1 virus (original SARS-CoV-2) and the Delta variant. The Delta variant became the dominant variant ( ⩾ 99%) as most of our participants were reaching T4, thus, we mainly focused on the Delta variant at this time point. Participants gradually received BNT162b2 booster shots after T3 until the endpoint of our study.
Nebnext Umi Rna Adaptors, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nebnext umi rna adaptors/product/New England Biolabs
Average 96 stars, based on 1 article reviews
nebnext umi rna adaptors - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
nebnext umi rna adapters  (New England Biolabs)
96
New England Biolabs nebnext umi rna adapters
Study design and sampling time points. Participants included naïve and convalescent individuals given either two or three doses of Pfizer vaccine; a convalescent individual given the J&J vaccine; and unvaccinated convalescent individuals. Viral RNA, antibodies against S or N proteins, and inhibition capacities against the viral receptor-binding domain (RBD) of <t>SARS-CoV-2</t> were evaluated at T1 (2 weeks post the first dose) and T2 (2 weeks post the second dose) in individual participants. At T3 (24 weeks post the first dose or ~5 months postvaccination) and T4 (36 weeks post the first dose or ~8 months postvaccination), viral RNA, antibodies against S or N proteins of SARS-CoV-2, and neutralizing antibodies were evaluated by live-virus-based microneutralization assay. Since the Delta variant emerged (around T3), we evaluated neutralization capacities against the basal B.1 virus (original SARS-CoV-2) and the Delta variant. The Delta variant became the dominant variant ( ⩾ 99%) as most of our participants were reaching T4, thus, we mainly focused on the Delta variant at this time point. Participants gradually received BNT162b2 booster shots after T3 until the endpoint of our study.
Nebnext Umi Rna Adapters, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nebnext umi rna adapters/product/New England Biolabs
Average 96 stars, based on 1 article reviews
nebnext umi rna adapters - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
e7760l nebnext multiplex oligos for illumina unique dual index umi adapters rna set 1  (New England Biolabs)
96
New England Biolabs e7760l nebnext multiplex oligos for illumina unique dual index umi adapters rna set 1
Study design and sampling time points. Participants included naïve and convalescent individuals given either two or three doses of Pfizer vaccine; a convalescent individual given the J&J vaccine; and unvaccinated convalescent individuals. Viral RNA, antibodies against S or N proteins, and inhibition capacities against the viral receptor-binding domain (RBD) of <t>SARS-CoV-2</t> were evaluated at T1 (2 weeks post the first dose) and T2 (2 weeks post the second dose) in individual participants. At T3 (24 weeks post the first dose or ~5 months postvaccination) and T4 (36 weeks post the first dose or ~8 months postvaccination), viral RNA, antibodies against S or N proteins of SARS-CoV-2, and neutralizing antibodies were evaluated by live-virus-based microneutralization assay. Since the Delta variant emerged (around T3), we evaluated neutralization capacities against the basal B.1 virus (original SARS-CoV-2) and the Delta variant. The Delta variant became the dominant variant ( ⩾ 99%) as most of our participants were reaching T4, thus, we mainly focused on the Delta variant at this time point. Participants gradually received BNT162b2 booster shots after T3 until the endpoint of our study.
E7760l Nebnext Multiplex Oligos For Illumina Unique Dual Index Umi Adapters Rna Set 1, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/e7760l nebnext multiplex oligos for illumina unique dual index umi adapters rna set 1/product/New England Biolabs
Average 96 stars, based on 1 article reviews
e7760l nebnext multiplex oligos for illumina unique dual index umi adapters rna set 1 - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
adapter ligation method  (New England Biolabs)
96
New England Biolabs adapter ligation method
Study design and sampling time points. Participants included naïve and convalescent individuals given either two or three doses of Pfizer vaccine; a convalescent individual given the J&J vaccine; and unvaccinated convalescent individuals. Viral RNA, antibodies against S or N proteins, and inhibition capacities against the viral receptor-binding domain (RBD) of <t>SARS-CoV-2</t> were evaluated at T1 (2 weeks post the first dose) and T2 (2 weeks post the second dose) in individual participants. At T3 (24 weeks post the first dose or ~5 months postvaccination) and T4 (36 weeks post the first dose or ~8 months postvaccination), viral RNA, antibodies against S or N proteins of SARS-CoV-2, and neutralizing antibodies were evaluated by live-virus-based microneutralization assay. Since the Delta variant emerged (around T3), we evaluated neutralization capacities against the basal B.1 virus (original SARS-CoV-2) and the Delta variant. The Delta variant became the dominant variant ( ⩾ 99%) as most of our participants were reaching T4, thus, we mainly focused on the Delta variant at this time point. Participants gradually received BNT162b2 booster shots after T3 until the endpoint of our study.
Adapter Ligation Method, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adapter ligation method/product/New England Biolabs
Average 96 stars, based on 1 article reviews
adapter ligation method - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
adapters e7330s  (New England Biolabs)
96
New England Biolabs adapters e7330s
Study design and sampling time points. Participants included naïve and convalescent individuals given either two or three doses of Pfizer vaccine; a convalescent individual given the J&J vaccine; and unvaccinated convalescent individuals. Viral RNA, antibodies against S or N proteins, and inhibition capacities against the viral receptor-binding domain (RBD) of <t>SARS-CoV-2</t> were evaluated at T1 (2 weeks post the first dose) and T2 (2 weeks post the second dose) in individual participants. At T3 (24 weeks post the first dose or ~5 months postvaccination) and T4 (36 weeks post the first dose or ~8 months postvaccination), viral RNA, antibodies against S or N proteins of SARS-CoV-2, and neutralizing antibodies were evaluated by live-virus-based microneutralization assay. Since the Delta variant emerged (around T3), we evaluated neutralization capacities against the basal B.1 virus (original SARS-CoV-2) and the Delta variant. The Delta variant became the dominant variant ( ⩾ 99%) as most of our participants were reaching T4, thus, we mainly focused on the Delta variant at this time point. Participants gradually received BNT162b2 booster shots after T3 until the endpoint of our study.
Adapters E7330s, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adapters e7330s/product/New England Biolabs
Average 96 stars, based on 1 article reviews
adapters e7330s - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
umi adapters  (Illumina Inc)
99
Illumina Inc umi adapters
Study design and sampling time points. Participants included naïve and convalescent individuals given either two or three doses of Pfizer vaccine; a convalescent individual given the J&J vaccine; and unvaccinated convalescent individuals. Viral RNA, antibodies against S or N proteins, and inhibition capacities against the viral receptor-binding domain (RBD) of <t>SARS-CoV-2</t> were evaluated at T1 (2 weeks post the first dose) and T2 (2 weeks post the second dose) in individual participants. At T3 (24 weeks post the first dose or ~5 months postvaccination) and T4 (36 weeks post the first dose or ~8 months postvaccination), viral RNA, antibodies against S or N proteins of SARS-CoV-2, and neutralizing antibodies were evaluated by live-virus-based microneutralization assay. Since the Delta variant emerged (around T3), we evaluated neutralization capacities against the basal B.1 virus (original SARS-CoV-2) and the Delta variant. The Delta variant became the dominant variant ( ⩾ 99%) as most of our participants were reaching T4, thus, we mainly focused on the Delta variant at this time point. Participants gradually received BNT162b2 booster shots after T3 until the endpoint of our study.
Umi Adapters, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/umi adapters/product/Illumina Inc
Average 99 stars, based on 1 article reviews
umi adapters - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
nebnext ultratm ll directional rna library prep kit  (New England Biolabs)
96
New England Biolabs nebnext ultratm ll directional rna library prep kit
Study design and sampling time points. Participants included naïve and convalescent individuals given either two or three doses of Pfizer vaccine; a convalescent individual given the J&J vaccine; and unvaccinated convalescent individuals. Viral RNA, antibodies against S or N proteins, and inhibition capacities against the viral receptor-binding domain (RBD) of <t>SARS-CoV-2</t> were evaluated at T1 (2 weeks post the first dose) and T2 (2 weeks post the second dose) in individual participants. At T3 (24 weeks post the first dose or ~5 months postvaccination) and T4 (36 weeks post the first dose or ~8 months postvaccination), viral RNA, antibodies against S or N proteins of SARS-CoV-2, and neutralizing antibodies were evaluated by live-virus-based microneutralization assay. Since the Delta variant emerged (around T3), we evaluated neutralization capacities against the basal B.1 virus (original SARS-CoV-2) and the Delta variant. The Delta variant became the dominant variant ( ⩾ 99%) as most of our participants were reaching T4, thus, we mainly focused on the Delta variant at this time point. Participants gradually received BNT162b2 booster shots after T3 until the endpoint of our study.
Nebnext Ultratm Ll Directional Rna Library Prep Kit, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nebnext ultratm ll directional rna library prep kit/product/New England Biolabs
Average 96 stars, based on 1 article reviews
nebnext ultratm ll directional rna library prep kit - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
rxn claretbio cbs cb 24 nebnext ultra ii dna library prep kit for illumina neb e7645s unique dual index umi adapters rna  (New England Biolabs)
96
New England Biolabs rxn claretbio cbs cb 24 nebnext ultra ii dna library prep kit for illumina neb e7645s unique dual index umi adapters rna
Study design and sampling time points. Participants included naïve and convalescent individuals given either two or three doses of Pfizer vaccine; a convalescent individual given the J&J vaccine; and unvaccinated convalescent individuals. Viral RNA, antibodies against S or N proteins, and inhibition capacities against the viral receptor-binding domain (RBD) of <t>SARS-CoV-2</t> were evaluated at T1 (2 weeks post the first dose) and T2 (2 weeks post the second dose) in individual participants. At T3 (24 weeks post the first dose or ~5 months postvaccination) and T4 (36 weeks post the first dose or ~8 months postvaccination), viral RNA, antibodies against S or N proteins of SARS-CoV-2, and neutralizing antibodies were evaluated by live-virus-based microneutralization assay. Since the Delta variant emerged (around T3), we evaluated neutralization capacities against the basal B.1 virus (original SARS-CoV-2) and the Delta variant. The Delta variant became the dominant variant ( ⩾ 99%) as most of our participants were reaching T4, thus, we mainly focused on the Delta variant at this time point. Participants gradually received BNT162b2 booster shots after T3 until the endpoint of our study.
Rxn Claretbio Cbs Cb 24 Nebnext Ultra Ii Dna Library Prep Kit For Illumina Neb E7645s Unique Dual Index Umi Adapters Rna, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rxn claretbio cbs cb 24 nebnext ultra ii dna library prep kit for illumina neb e7645s unique dual index umi adapters rna/product/New England Biolabs
Average 96 stars, based on 1 article reviews
rxn claretbio cbs cb 24 nebnext ultra ii dna library prep kit for illumina neb e7645s unique dual index umi adapters rna - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


Study design and sampling time points. Participants included naïve and convalescent individuals given either two or three doses of Pfizer vaccine; a convalescent individual given the J&J vaccine; and unvaccinated convalescent individuals. Viral RNA, antibodies against S or N proteins, and inhibition capacities against the viral receptor-binding domain (RBD) of SARS-CoV-2 were evaluated at T1 (2 weeks post the first dose) and T2 (2 weeks post the second dose) in individual participants. At T3 (24 weeks post the first dose or ~5 months postvaccination) and T4 (36 weeks post the first dose or ~8 months postvaccination), viral RNA, antibodies against S or N proteins of SARS-CoV-2, and neutralizing antibodies were evaluated by live-virus-based microneutralization assay. Since the Delta variant emerged (around T3), we evaluated neutralization capacities against the basal B.1 virus (original SARS-CoV-2) and the Delta variant. The Delta variant became the dominant variant ( ⩾ 99%) as most of our participants were reaching T4, thus, we mainly focused on the Delta variant at this time point. Participants gradually received BNT162b2 booster shots after T3 until the endpoint of our study.

Journal: Experimental Biology and Medicine

Article Title: Absence of antibody responses to SARS-CoV-2 N protein in COVID-19 vaccine breakthrough cases

doi: 10.1177/15353702221134097

Figure Lengend Snippet: Study design and sampling time points. Participants included naïve and convalescent individuals given either two or three doses of Pfizer vaccine; a convalescent individual given the J&J vaccine; and unvaccinated convalescent individuals. Viral RNA, antibodies against S or N proteins, and inhibition capacities against the viral receptor-binding domain (RBD) of SARS-CoV-2 were evaluated at T1 (2 weeks post the first dose) and T2 (2 weeks post the second dose) in individual participants. At T3 (24 weeks post the first dose or ~5 months postvaccination) and T4 (36 weeks post the first dose or ~8 months postvaccination), viral RNA, antibodies against S or N proteins of SARS-CoV-2, and neutralizing antibodies were evaluated by live-virus-based microneutralization assay. Since the Delta variant emerged (around T3), we evaluated neutralization capacities against the basal B.1 virus (original SARS-CoV-2) and the Delta variant. The Delta variant became the dominant variant ( ⩾ 99%) as most of our participants were reaching T4, thus, we mainly focused on the Delta variant at this time point. Participants gradually received BNT162b2 booster shots after T3 until the endpoint of our study.

Article Snippet: Viral RNA was detected by (qRT-PCR using FDA-approved Luminex SARS-CoV-2 panel 2 (IDT, Cat# 10006941).

Techniques: Sampling, Inhibition, Binding Assay, Microneutralization Assay, Variant Assay, Neutralization

Reduced neutralizing capacity against SARS-CoV-2 Delta variant at 5 months postvaccination and in unvaccinated convalescent individuals. (a) Correlation between neutralization capacities (presented as EC50: half-maximal effective concentration) against B.1-isolate and Delta variant as evidenced by the Spearman correlation coefficient. (b) Neutralization capacities against B.1-isolate (top panels) and Delta variant (bottom panels) in older Vac_naive individuals as compared to younger Vac_naive individuals. Significance was determined using two-sided Mann–Whitney U tests. (c) Age-adjusted neutralization capacities against Delta (filled circles) compared to those against B.1-isolate (open circles). #: Significance was determined using the two-sided Kruskal–Wallis test followed by a two-stage-step-up Benjamini, Krieger, and Yekutieli false discovery rate method for multiple comparison correction. &: The rank ANCOVA was used to evaluate neutralization capacities across study groups, while controlling for the confounding effect of age. The rank ANCOVA results were presented at F -distribution with p -value. The rank ANCOVA was followed by two-sided Dunnett’s post hoc tests to correct multiple comparisons.

Journal: Experimental Biology and Medicine

Article Title: Absence of antibody responses to SARS-CoV-2 N protein in COVID-19 vaccine breakthrough cases

doi: 10.1177/15353702221134097

Figure Lengend Snippet: Reduced neutralizing capacity against SARS-CoV-2 Delta variant at 5 months postvaccination and in unvaccinated convalescent individuals. (a) Correlation between neutralization capacities (presented as EC50: half-maximal effective concentration) against B.1-isolate and Delta variant as evidenced by the Spearman correlation coefficient. (b) Neutralization capacities against B.1-isolate (top panels) and Delta variant (bottom panels) in older Vac_naive individuals as compared to younger Vac_naive individuals. Significance was determined using two-sided Mann–Whitney U tests. (c) Age-adjusted neutralization capacities against Delta (filled circles) compared to those against B.1-isolate (open circles). #: Significance was determined using the two-sided Kruskal–Wallis test followed by a two-stage-step-up Benjamini, Krieger, and Yekutieli false discovery rate method for multiple comparison correction. &: The rank ANCOVA was used to evaluate neutralization capacities across study groups, while controlling for the confounding effect of age. The rank ANCOVA results were presented at F -distribution with p -value. The rank ANCOVA was followed by two-sided Dunnett’s post hoc tests to correct multiple comparisons.

Article Snippet: Viral RNA was detected by (qRT-PCR using FDA-approved Luminex SARS-CoV-2 panel 2 (IDT, Cat# 10006941).

Techniques: Variant Assay, Neutralization, Concentration Assay, MANN-WHITNEY